SEC Form 4 · accession 0001209191-17-059614
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Mark Wechsler
Officer — President and CEO · Director
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 4:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.63 | Nov 3, 2017 | A | 550,981 | A | — | Nov 3, 2027 | Common Stock | 550,981 | 550,981 | D |
| Restricted Stock UnitsF1 | $0.00 | Nov 3, 2017 | A | 183,661 | A | — | — | Common Stock | 183,661 | 183,661 | D |
Explanation of responses
- F1The award vests 25% on November 3, 2018 and the remainder will vest in equal monthly installments during the 3 years following the initial vesting date, subject to the Reporting Person's continued employment with the Issuer.